A Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

About this Study

The purpose of this study is to compare the good and bad effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin. 

Sponsor Protocol ID:NRG-BR003
IRB Number:2015-0236
Closed for Enrollment
Interventional
Phase 3
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion CriteriaNone

Exclusion CriteriaNone

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Shou-Ching Tang
How to participate in our Clinical Trials